CSL Behring Commits $670 Million to Expand Plasma Therapy Manufacturing in Marburg, Germany

project_news

CSL Behring Commits $670 Million to Expand Plasma Therapy Manufacturing in Marburg, Germany

Updated on Nov 20, 2026, 10:53 PM IST
Written & Edited by Harikesh VA

CSL (ASX:CSL) has announced plans to invest approximately USD 670 million in its Marburg, Germany, site through 2030, aiming to expand capacity for producing critical plasma-derived therapies (PDTs) for people living with rare, chronic, and serious diseases.

 

The company described the investment as a long-term commitment to manufacturing complex plasma-derived therapies in Europe, supplying patients in more than 100 countries as global demand grows.

 

Investment to Strengthen Health Supply Resilience

The announcement was made at the "Marburg 2030 – Building What's Next" event held at the site, attended by around 100 guests from politics, public administration, business, science, trade unions, and associations.

 

CSL said the investment is intended to strengthen the site's role in health security and supply resilience across Europe, where many patients depend on these therapies for life.

 

 

Scale of Current Operations

In FY2025/26, the Marburg site produced well over 18 million packs of finished, packaged units of medicine, such as a vial or syringe in a carton, and carried out around 5,000 production batch releases, supplying patients with PDTs and other therapies in more than 100 countries. CSL manufactures complex plasma-derived and hyperimmune therapies at scale at its sites in Marburg and Bern, Switzerland.

Immunoglobulins and other plasma-derived therapies are essential for people with conditions such as primary immunodeficiencies (PIDs), haemophilia, and hereditary angioedema, according to the company. These therapies are also used in emergency medicine, major surgery, and critical care.

Trusted by Leading EPCs & Manufacturers

Find the Latest Pharmaceutical Plant Projects in Germany

Gain exclusive access to our industry-leading database of pharmaceutical plant opportunities with detailed project timelines and stakeholder information

Request Free Trial → Learn More →

No credit card Up-to-date coverage

 

New Filling Lines and Fibrinogen Facility

The USD 670 million investment will fund two new filling lines with eight freeze dryers for PDTs. Once operational, which is expected in 2029, the new lines will further expand Marburg's freeze-drying capacity. The investment will also fund a new bulk facility for fibrinogen, a plasma protein essential for blood clotting.

CSL stated that advanced facilities, automation, and digital process control support long-term manufacturing resilience and supply continuity.

"This investment is about preparing Marburg for the future. By strengthening our manufacturing capabilities, we are reinforcing the site's long-term role within CSL's manufacturing network and our ability to reliably supply plasma-derived therapies to patients," said Dr. Niklas Schier, VP and Site Head Marburg, CSL.

 

"More than 300,000 patients in Europe depend on these therapies, and global demand continues to grow. With this investment, we are strengthening our biopharmaceutical manufacturing in Europe to deliver them here and around the world."

Dependence on Plasma Donations

CSL emphasized that most plasma proteins cannot be made synthetically, meaning these therapies depend on donations from healthy volunteers.

 

An estimated 130 donations are needed to treat one person with PID for a year and around 1,200 donations for one person with severe haemophilia. Turning donated plasma into a finished therapy takes months of highly specialised manufacturing, according to the company.

Because of these characteristics, PDTs require sustained investment in both collection and manufacturing. Together with CSL Plasma's donation centres, Marburg forms part of an integrated network that connects donors to patients.

"Every therapy we make in Marburg starts with a donation and ends with a patient. Plasma-derived therapies are fundamentally different from conventional pharmaceuticals because they depend on human donations and a long, complex manufacturing process," said Annegret Wittich-Hoeffer, VP and Cluster Head DACH, CSL.

 

"As the EU works to strengthen the security of supply of critical medicines, our investment in the Marburg site contributes to a resilient European supply to ensure reliable access."

European Supply Security Context

The announcement comes as the European Union works to strengthen the security of supply of critical medicines. CSL noted that it continues to work with stakeholders across Europe to support the manufacturing of PDTs in Europe.

The company framed the Marburg investment as contributing to reliable access for the more than 300,000 European patients who depend on these therapies while also serving global demand.

 

CSL stated that global demand for plasma-derived therapies continues to grow and that the expansion positions the Marburg site to supply patients in Europe and around the world.

About CSL

CSL (ASX:CSL; USOTC:CSLLY) describes itself as a leading global biopharma company with a portfolio of medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis, and nephrology.

 

Founded in 1916, the company operates through three businesses, CSL Behring, CSL Seqirus, and CSL Vifor, and provides products to patients in more than 100 countries, employing almost 29,000 people.

Stay Ahead of Germany's Chemical Project Pipeline

Which chemical megaprojects in Germany will break ground next quarter, and will your business be positioned to capture them? From chemical plant expansions to innovative developments, the region's chemical sector is advancing at an unprecedented pace. Having timely, verified intelligence on these opportunities can make the difference between securing a contract and losing it to a competitor.

 

The Global Project Tracking (GPT) platform by Blackridge Research gives you a live view of chemical activity across Germany, helping you identify prospects early, track progress at every stage, and connect with the right decision-makers at the right time.

 

  • Upcoming Projects

  • Tender Notices

  • Contract Awards

  • Projects Under Construction

  • Completed Projects

 

Ready to see how it works? Book a Free Demo today and discover how the Global Project Tracking (GPT) platform by Blackridge Research can power your chemical growth strategy in Germany.

Tags

Leave a Comment

We love hearing from our readers and value your feedback. If you have any questions or comments about our content, feel free to leave a comment below.

We read every comment and do our best to respond to them all.

Protected by Cloudflare Turnstile